Longevity Physician|Hormones|| Precision Medicine Using Medicine 3.0 to help patients improve their health and optimize performance
New York, NY
Joined July 2012
- Tweets6.8K
- Following4.5K
- Followers3K
- Likes11.2K
Already can't stop laughing at these RUO distributors promoting RUO and saying that will stil be mainstay. Prices for a month dose of quality peptide has already dropped 33-50% in 2 days since announcement. That is before the competitionm really starts and prices go lower. Why risk using RUO for like $10/month
Dr. Neil Paulvin retweeted
🚨 Neuralink just delivered one of its most emotional breakthroughs yet
Terry, diagnosed with ALS in 2024, is now speaking again using only his thoughts.
The implant translates brain signals into words, with Grok Voice restoring his own natural voice.
Watching him hear himself speak again is incredibly powerful.
This is what restoring human connection looks like. Truly life-changing. As found.
Dr. Neil Paulvin retweeted
Histone Modifications at the Intersection of Aging, Neuroinflammation and Metabolism in Alzheimer's Disease
onlinelibrary.wiley.com/doi/…
Dr. Neil Paulvin retweeted
Special shoutout to @LeeRosebush for leading the charge. Also to the OG behind this all, @pradeepalbertmd
Dr. Neil Paulvin retweeted
#Breaking: FDA offers new details on quicker approval pathway for personalized gene therapies statnews.com/2026/10/27/fda-…
Dr. Neil Paulvin retweeted
High blood pressure, diabetes, and smoking in your mid-50s were linked to almost 13 fewer years free of dementia.
In ARIC, a US study of 12,409 people, researchers tracked these three risk factors for 26 years. By age 55, people with none of them lived about 30 more years free of dementia. People with all three got about 17.
Most of the lost time was from earlier death. By 75, half of those with all three had died without ever getting dementia, compared with 1 in 10 people with none. Dementia also arrived sooner.
The pattern was dose-dependent. One risk factor was linked to about 4 fewer dementia-free years. Two were linked to about 9.
Bottom line: the same numbers doctors watch for heart health also tracked how long people stayed free of dementia. This was observational, and only 176 people had all three risks, so it cannot prove treatment would give those years back.
Blood pressure and blood sugar are easy to check and treat. If you smoke, ask for help to quit.
Dr. Neil Paulvin retweeted
BREAKING: AstraZeneca reports major breakthrough in stomach cancer treatment, with its experimental drug reducing the risk of death by 53% compared with chemotherapy in a late-stage trial.
Dr. Neil Paulvin retweeted
One of the world's biggest cancer conferences is happening right now. Here are 5 breakthroughs they're talking about:
1. The world's leading cause of cancer death (lung cancer) now has a therapy that cut the risk of death by 58%, moving median survival from 12.7 to 21.1 months (small cell lung cancer).
2. A new personalized therapy for Melanoma can train the immune system in cancer patients and alongside a common cancer med, it cut the risk of recurrence or death by 42%.
3. A therapy has been FDA approved to allow certain people with a subset of rectal cancers to skip chemo, radiation, and surgery. Around half of patients so far were cancer free over a year later. Colorectal cancer is the deadliest cancer in Americans under 50.
4. Chinese researchers presented data on a new therapy for breast cancer where it more than doubled the time before the cancer began to worsen.
5. Another huge therapy saw median survival increase by almost 50% in a specific mutated type of lung cancer, while also lowering decreasing severe side effects. (NSCLC type)
See sources below.
Dr. Neil Paulvin retweeted
🚨: MIT scientists create injectable gel that regrows damaged nerves, restores sensation completely
Dr. Neil Paulvin retweeted
the 2026 cholesterol guideline now names south asian ancestry a risk enhancer. new acc review says look past ldl: lp(a), apoB (count of plaque particles), and a calcium score of 0 isn't a free pass since we get more soft plaque.
Dr. Neil Paulvin retweeted
GDF15 is the best biomarker of energetic stress we have. Psilocybin is one of the most powerful medicines that alter states of mind and stimulate the healing process.
Intriguing results linking psilocybin and GDF15 in people with Parkinson’s disease.
Mitochondrial stress (GDF-15) is reduced in Parkinson's disease patients after psilocybin administration (Bradley et al.: jamanetwork.com/journals/jam…)
This supports our hypothesis that #psychedelics affect mitochondria (journals.sagepub.com/doi/abs…)
Dr. Neil Paulvin retweeted
These guys never reported their primary endpoint. Because they didn’t like it.
So now blaming @Cleerlyhealth because they got the answer they liked with “re-analysis”. It should have never been accepted for publication but it is ridiculous to blame Cleerly for this. Show us the data to justify this.
We, the authors, retracted the paper, @Drlipid
This was due to the anomalous @Cleerlyhealth dataset they provided us alongside their repeated refusal to quality control check their work.
Study participants have since resubmitted their scans and have gotten results far more in line with the other independent analyses from Heartflow and QAngio.
So yes, understandably, we moved to withdraw the paper leading to its retraction.
(This has been known for over half year now.)
nitter.cf/realDaveFeldman/status…
Dr. Neil Paulvin retweeted
NEW: Former OpenAI science head Kevin Weil launches Warp Sciences with a $215M Series A led by Lightspeed.
The company is building AI-powered robotic labs for drug discovery, where AI designs experiments, robots run them, and the results train better models.
Dr. Neil Paulvin retweeted
We’re glad to share our partnership with Bayer to bring Biomni Lab, our frontier AI co-scientist platform, to its scientific research teams. Researchers will harness Biomni Lab’s agentic capabilities to tackle complex scientific questions, accelerate the path from insight to decision, and scale AI-enabled research workflows across the organization.
Phylo is building toward a future where scientists across the world’s leading life science organizations can direct teams of AI agents to drive new discoveries. This partnership represents a significant step toward realizing that vision.
Read more: phylo.bio/blog/bayer-partner…
Dr. Neil Paulvin retweeted
Over 85% of oncologists at Memorial Sloan Kettering Cancer Center use OpenEvidence.
Together, @MSKCancerCenter and OpenEvidence have built OncoKB, MSK’s expert interpretation of a tumor’s genetics, directly into OpenEvidence, putting it in the hands of oncologists across the United States.
As Dr. Anaeze Offodile puts it: “Our mission is to end cancer for life.” As of today, we are widening OncoKB’s reach so that patients everywhere benefit from the same rigor as patients at MSK. Watch the story.
Dr. Neil Paulvin retweeted
the ama has a new framework for agentic ai in care. how much a tool may do depends on the evidence behind it. it also says who answers when it fails. use it before adopting anything that triages, orders or titrates. news.longevitydocs.org/techn…
Dr. Neil Paulvin retweeted
🚨 Lilly just made another deal that could quietly matter A LOT for the future of obesity treatment.
$LLY is partnering with METiS TechBio in a deal worth up to $1.1 BILLION to develop AI-designed lipid nanoparticles capable of delivering therapies to specific tissues.
This isn’t an obesity-specific deal. But think bigger than another GLP-1.
If Lilly can eventually use this technology to deliver RNA, gene-editing tools or other therapeutic payloads directly into metabolic tissues, we could be talking about drugs designed to alter obesity biology much closer to the source, potentially with very different dosing and durability than today’s weekly injections.
The obesity market is rapidly becoming much bigger than “who has the best GLP-1.”
I’m hopeful for a future where we get to the root causes of metabolic dysfunction and disease. This feels like Lilly taking a step in that direction.